Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Dezember 2023 - 10:30PM
Business Wire
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
reported the grant in December of an aggregate of 28,328 restricted
stock units (RSUs) of the company’s common stock to 7 newly hired
non-executive employees of the company. The awards were approved by
the compensation committee of the company’s board of directors
under the Evolus’ 2023 Inducement Incentive Plan, with a grant date
and vesting commencement date of December 7, 2023, as an inducement
material to the new employees entering into employment with Evolus
in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on each annual anniversary of the vesting
commencement date. The awards are subject to the terms and
conditions of the 2023 Inducement Incentive Plan and the terms and
conditions of the RSU agreement covering the grant, including
requirements to remain continuously employed on each vesting
date.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the
brand name Nuceiva®. The product is manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, Twitter,
Instagram or Facebook.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of
Daewoong Pharmaceutical Co, Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231208831612/en/
Investor Contacts: Ned
Mitchell Arbor Advisory Group Email: ir@evolus.com
Media Contact: Email:
media@evolus.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024